Accelerate the transformation and innovation of pharmaceutical enterprises with volume procurement, and usher in the golden age of CRO

[pharmaceutical network market analysis] "4 + 7" volume procurement, medical insurance catalog adjustment and other heavy combination of medical insurance cost control, so that pharmaceutical companies are more aware of the coming of a new era of medicine Benefiting from the rise of innovative drugs and the "consistency evaluation" of pharmaceutical enterprises in order to win the bid for "volume procurement", the domestic research outsourcing service (CRO) industry not only faces new opportunities, but also ushers in a golden age of development and growth It is understood that cro's business covers drug discovery, preclinical research, clinical research, new drug registration and application, etc., which is essentially an industry formed by a high degree of division of labor in the pharmaceutical industry At present, China's new drug R & D outsourcing service has formed a complete industrial chain, which can provide services including new drug product development, pre clinical trial and clinical trial, data management and new drug application, almost covering the whole process of new drug R & D For large pharmaceutical enterprises, only from the aspect of drug R & D, outsourcing of R & D business can make them disperse risks and carry out R & D business more efficiently But in fact, for the current development of domestic cro industry, more opportunities are reflected in small pharmaceutical enterprises The reason behind this is that China's pharmaceutical financing volume is growing rapidly The new regulations and the establishment of science and Technology Innovation Board of Hong Kong stock exchange for Biopharmaceutical Enterprises can promote Biopharmaceutical Enterprises to obtain financing from the secondary market Many small pharmaceutical companies have sufficient funds However, due to the lack of their own facilities and R & D personnel, most small pharmaceutical enterprises need to rely on drug R & D and production service companies to complete clinical development and other work From the perspective of global market, the pharmaceutical R & D outsourcing service industry is in the rising stage with high prosperity According to the forecast of Frost & Sullivan report, in 2018, the global market scale of new drug R & D outsourcing services will be about 115 billion US dollars, and will grow to 178.5 billion US dollars by 2022, with an annual compound growth rate of about 11.6% With the continuous growth of global innovative drugs and the rising cost of R & D, the penetration rate of outsourcing will further improve The domestic pharmaceutical R & D outsourcing service industry is further developing and expanding under the influence of global industrial transfer and China pharmaceutical innovation driving factors Domestic cro industry giants such as Wuxi Wuxi Pharmaceutical Co., Ltd., tiger Pharmaceutical Co., Ltd., Boji Pharmaceutical Co., Ltd and KANGLONG Chemical Industry Co., Ltd have gained more and more development opportunities Taking Wuxi apptec as an example, in its previous half year report, its revenue from clinical research and other cro services reached 472 million yuan, an increase of 104.22% year-on-year On the whole, at present, a series of measures such as drug review and approval reform are still speeding up the listing of new drugs in China In addition, since 2019, with the continuous deepening of "4 + 7" volume procurement and other policies, as well as the launch of science and technology innovation board, science and technology innovation enterprises, including Biopharmaceutical Enterprises, will further attach importance to R & D and innovation, which will continue to promote the future development of pharmaceutical R & D outsourcing service industry However, it is worth noting that with the development of cro, the supporting software and hardware need to keep up, such as the domestic security capacity of high-end materials and key materials required by cro industry, and the need to further improve the MAH (listing licensor) system, as well as the involvement of the third-party insurance mechanism Only when these are complete, can the industry develop better and healthier.